2-methyl-1,1,4-trioxo-1,2,3,4-tetrahydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carboxylic acid 5-methyl-thiazol-2-ylamide | 61764-23-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2-methyl-1,1,4-trioxo-1,2,3,4-tetrahydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carboxylic acid 5-methyl-thiazol-2-ylamide
• 英文别名: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-naphtho[2,1-e]-1,2-thiazine-3-carboxamide-1,1-dioxide；4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxobenzo[h][1,2]benzothiazine-3-carboxamide
• CAS: 61764-23-6
• 化学式: C₁₈H₁₅N₃O₄S₂
• 分子量: 401.467
• InChiKey: RRJNDFVLWNZEGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,3-Dihydronaphth[2,1-d]isothiazol-3(2H)-one 1,1-dioxide 在 甲醇 、 sodium hydroxide 、 sodium methylate 、 sodium hydride 作用下， 以 乙醇 、 甲苯 、 xylene 为溶剂， 反应 80.5h， 生成 2-methyl-1,1,4-trioxo-1,2,3,4-tetrahydro-1λ⁶-naphtho[2,1-e][1,2]thiazine-3-carboxylic acid 5-methyl-thiazol-2-ylamide
  参考文献：
  名称：

  Effect of Structural Modification of Enol−Carboxamide-Type Nonsteroidal Antiinflammatory Drugs on COX-2/COX-1 Selectivity

  摘要：

  Meloxicam (5), an NSAID in the enol-carboxamide class, was developed on the basis of its antiinflammatory activity and relative safety in animal models. In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs. We therefore embarked on a study of enol-carboxamide type compounds to determine if COX-2 selectivity and potency could be dramatically improved by structural modification. Substitution at the 6- and 7-positions of the 4-oxo-1,2-benzothiazine-3-carboxamide, alteration of the N-methyl substituent, and amide modification were all examined. In addition we explored several related systems including the isomeric 3-oxo-1,2-benzothiazine-4-carboxamides, thienothiazines, indolothiazines, benzothienothiazines, naphthothiazines, and 1,3- and 1,4-dioxoisoquinolines. While a few examples were found with greater potency in the COX-2 assay, no compound tested had a better COX-2/COX-1 selectivity profile than that of 5.

  DOI：

  10.1021/jm9607010

文献信息

• 4-Hydroxy-2H-naphtho[2,1-e]-1,2-thiazine-3-carboxamide-1,1-dioxides and
  申请人：Boehringer Ingelheim GmbH

  公开号：US03992535A1

  公开（公告）日：1976-11-16

  Compounds of the formula ##SPC1## Wherein R.sub.1 is hydrogen, methyl or ethyl, and Ar is phenyl, 3-chlorophenyl, 3-bromophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-tolyl, 2-methoxyphenyl, 3-methoxyphenyl, 2-pyridyl, 4-methyl-2-pyridyl, 6-methyl-2-pyridyl, 3-hydroxy-2-pyridyl, 3-pyridyl, 4-pyridyl, 6-chloro-3-pyridazinyl, 2-pyrazinyl, 6-chloro-2-pyrazinyl, 6-chloro-4-pyrimidinyl, 2-thiazolyl, 4-methyl-2-thiazolyl, 4-ethyl-2-thiazolyl, 5-methyl-2-thiazolyl, 5-ethyl-2-thiazolyl, 4,5-dimethyl-2-thiazolyl, 4-ethyl-5-methyl-2-thiazolyl, 5-ethyl-4-methyl-2-thiazolyl, 2-benzothiazolyl, 4,5,6,7-tetrahydro-2-benzothiazolyl, 5,6-dihydro-7H-thiopyrano[4,3-d]thiazol-2-yl, 3-methyl-5-isothiazolyl, 1,3,4-thiadiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl or 5-methyl-3-isoxazolyl, And non-toxic, pharmacologically acceptable salts thereof formed with an inorganic or organic base; the compounds as well as their salts are useful as inhibitors of platelet adhesion and aggregation.

  式##SPC1##的化合物，其中R1为氢、甲基或乙基，Ar为苯基、3-氯苯基、3-溴苯基、2-氟苯基、3-氟苯基、4-氟苯基、3-甲苯基、2-甲氧基苯基、3-甲氧基苯基、2-吡啶基、4-甲基-2-吡啶基、6-甲基-2-吡啶基、3-羟基-2-吡啶基、3-吡啶基、4-吡啶基、6-氯-3-哒嗪基、2-嘧啶基、6-氯-2-嘧啶基、6-氯-4-嘧啶基、2-噻唑基、4-甲基-2-噻唑基、4-乙基-2-噻唑基、5-甲基-2-噻唑基、5-乙基-2-噻唑基、4,5-二甲基-2-噻唑基、4-乙基-5-甲基-2-噻唑基、5-乙基-4-甲基-2-噻唑基、2-苯并噻唑基、4,5,6,7-四氢-2-苯并噻唑基、5,6-二氢-7H-噻喃并[4,3-d]噻唑-2-基、3-甲基-5-异噻唑基、1,3,4-噻二唑基、5-甲基-1,3,4-噻二唑-2-基或5-甲基-3-异噁唑基，以及与无机或有机碱形成的无毒、药学上可接受的盐；这些化合物及其盐可作为血小板粘附和聚集的抑制剂。
• US3992535A
  申请人：——

  公开号：US3992535A

  公开（公告）日：1976-11-16
• Effect of Structural Modification of Enol−Carboxamide-Type Nonsteroidal Antiinflammatory Drugs on COX-2/COX-1 Selectivity
  作者：Edward S. Lazer、Clara K. Miao、Charles L. Cywin、Ronald Sorcek、Hin-Chor Wong、Zhaoxing Meng、Ian Potocki、MaryAnn Hoermann、Roger J. Snow、Matt A. Tschantz、Terence A. Kelly、Daniel W. McNeil、Simon J. Coutts、Laurie Churchill、Anne G. Graham、Eva David、Peter M. Grob、Wolfhard Engel、Hans Meier、Günter Trummlitz

  DOI：10.1021/jm9607010

  日期：1997.3.1

  Meloxicam (5), an NSAID in the enol-carboxamide class, was developed on the basis of its antiinflammatory activity and relative safety in animal models. In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs. We therefore embarked on a study of enol-carboxamide type compounds to determine if COX-2 selectivity and potency could be dramatically improved by structural modification. Substitution at the 6- and 7-positions of the 4-oxo-1,2-benzothiazine-3-carboxamide, alteration of the N-methyl substituent, and amide modification were all examined. In addition we explored several related systems including the isomeric 3-oxo-1,2-benzothiazine-4-carboxamides, thienothiazines, indolothiazines, benzothienothiazines, naphthothiazines, and 1,3- and 1,4-dioxoisoquinolines. While a few examples were found with greater potency in the COX-2 assay, no compound tested had a better COX-2/COX-1 selectivity profile than that of 5.